XBIT Stock Overview
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XBiotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.95 |
| 52 Week High | US$9.96 |
| 52 Week Low | US$3.05 |
| Beta | 1.49 |
| 1 Month Change | 6.00% |
| 3 Month Change | 75.89% |
| 1 Year Change | 139.46% |
| 3 Year Change | -54.36% |
| 5 Year Change | -10.77% |
| Change since IPO | -64.99% |
Recent News & Updates
Recent updates
We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate
Feb 09
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely
Oct 25We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation
Jun 16XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
May 11Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares
Mar 18Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 08XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity
Nov 19Shareholder Returns
| XBIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | -2.5% | -3.2% |
| 1Y | 139.5% | -3.7% | 19.3% |
Return vs Industry: XBIT exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: XBIT exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| XBIT volatility | |
|---|---|
| XBIT Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XBIT's share price has been volatile over the past 3 months.
Volatility Over Time: XBIT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 82 | John Simard | www.xbiotech.com |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
XBiotech Inc. Fundamentals Summary
| XBIT fundamental statistics | |
|---|---|
| Market cap | US$242.08m |
| Earnings (TTM) | -US$24.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.9x
P/E RatioIs XBIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBIT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.56m |
| Earnings | -US$24.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XBIT perform over the long term?
See historical performance and comparison